Tonix Pharmaceuticals Aktie Logo
US8902608392
A40VM0
TPM0.DU

Tonix Pharmaceuticals Aktie

Loading quotes...

Forecast

The analysts' average price target is €20.51 (+784.05%). The median is €20.51 (+784.05%).

Buy
  6
Hold
  1
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Tonix Pharmaceuticals Aktie had revenue of €15.22m and net profit of -€47.08m
(EUR) September 2026
YoY
Revenue 15.22m 442.71%
Gross profit 14.11m 761.06%
Net profit -47.08m 72.61%
EBITDA -48.37m 79.92%

Fundamentals

Metric Value
Market capitalization
€52.96m
Number of shares
19.43m
52-week high/low
€18.74 - €2.56
Dividends No
Beta
1.90
P/E ratio
-0.24
PEG ratio
-0.01
P/B ratio
0.28
P/S ratio
1.35

Company profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Name
Tonix Pharmaceuticals Aktie
CEO
Seth Lederman
Headquarters Berkeley Heights, nj
USA
Website
Industry
Chemicals
IPO
10/05/2012
Employees 142

Ticker symbols

Exchange Symbol
Düsseldorf
TPM0.DU
🍪

Parqet  uses cookies. Learn more